

XBRANE BIOPHARMA AB ("XBRANE" OR THE "COMPANY") HAS ACCORDING TO PREVIOUSLY ANNOUNCED INFORMATION RESOLVED TO CARRY OUT A DIRECTED ISSUE OF IN TOTAL 25,990,000 SHARES

The new shares, which were issued following resolution by the board of directors on 10 June 2025 which was approved by the extra general meeting on 3 July 2025, have been allotted following approval from the Inspectorate for strategic products. As of 30 September 2025, the total number of shares and votes in the Company amounts to 2,575,668,555. The Company's registered share capital amounts to SEK 577,428,988.711063. The new shares were registered with the Swedish Companies Registration Office on 4 September 2025.

Contacts

Martin Åmark, CEO
E: martin.amark@xbrane.com

Jane Benyamin, CFO/IR
E: jane.benyamin@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-09-30 08:00 CEST.

Attachments

[XBRANE BIOPHARMA AB \("XBRANE" OR THE "COMPANY"\) HAS ACCORDING TO PREVIOUSLY ANNOUNCED INFORMATION RESOLVED TO CARRY OUT A DIRECTED ISSUE OF IN TOTAL 25,990,000 SHARES](#)